

Accuron *MedTech*

PRESS RELEASE

ACCURON MEDTECH PARTNERS WITH SPRING SINGAPORE TO CO-INVEST IN SINGAPORE'S INNOVATIVE START-UPS

- *Accuron MedTech appointed by SPRING Singapore to identify, co-invest and grow high-potential deep technology start-ups*
- *Accuron MedTech to invest S\$10 million in the Health and Biomedical Sciences sector*

Singapore, 8 February 2018 – Accuron MedTech Group (Accuron MedTech), Southeast Asia's largest medical device company, today announced that it has been appointed by SPRING SEEDS Capital (SSC), the investment arm of SPRING Singapore, to identify and catalyse the growth of high-potential Singapore-based start-ups. Accuron MedTech will invest up to S\$10 million in Singapore's Health and Biomedical Sciences sector and the investments will be matched by SSC.

In the last four years, Accuron MedTech has made more than 10 strategic investments in highly innovative, category disruptive technology start-ups – including renal disease companies Advent Access and AWAK Technologies, and ophthalmic company Peregrine Ophthalmic – that have the potential to revolutionise healthcare and transform the paradigm of patient treatment.

Accuron MedTech's investment will be made through the MTA2, a consortium of Economic Development Innovations Singapore (EDIS), Accuron MedTech and Mr Lu Yoh-Chie (LYC), the founder of Biosensors.

Abel Ang, Group Chief Executive of Accuron MedTech, said: *"We are seeing a growing pool of start-ups in Singapore and the Southeast Asia region that have the potential to make significant impact in healthcare, and are poised for rapid global commercial success.*

"As a leader in medical technology, Accuron MedTech is proud to partner with SPRING to be a mentor, and provide the network, resources and financial support to help technology entrepreneurs bring their innovations to a global market."

Investee companies will have access to Accuron MedTech's senior management team, which has more than 100+ years of international healthcare sector expertise, taking medical innovations from concept phase through to commercialisation worldwide.

"We are excited to be part of the Singapore start-up journey. We look forward to discover the first local-to-global success story, and put Singapore on the world map as a healthcare innovation hub," added **Mr Ang**.

###

For more information, please contact:

Wong Yau Chung
Accuron MedTech
+65 6572 6072
yc.wong@accuronmedtech.com

Stephanie Tan / Emma Thompson / Clarinda Ng
Spurwing Communications
+65 6340 7287
accuron@spurwingcomms.com

About Accuron MedTech

Accuron MedTech is the largest medical device company in Southeast Asia. It is a global medical technology leader with a core focus in urology devices and services. Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in 100 countries worldwide. Accuron MedTech makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Accuron MedTech is an independent division of Accuron Technologies, a wholly-owned subsidiary of Temasek Holdings. For more information on Accuron MedTech, please visit www.accuronmedtech.com.

About MTA 2

Established in 2018, the MTA2 is a Singapore accelerator investing in technology start-ups. MTA2 builds upon the experience of the Med-Tech Alliance which was formed in 2014, and has done four investments in medtech start-ups. The MTA2 consortium is made up of Economic Development Innovations Singapore (EDIS), Accuron MedTech Group (AMTG) and Mr. Lu Yoh-Chie (LYC), the founder of Biosensors. MTA2 aims to accelerate venture creation or start-up formation through financing and mentorship in three sectors – Health and Biomedical Sciences, Advanced Manufacturing & Engineering, and Urban Solutions and Sustainability.

About SPRING SEEDS Capital Pte Ltd (SSC)

SPRING SEEDS Capital (SSC), an investment arm of SPRING Singapore, co-invests with independent investor(s) in high potential Singapore-based start-ups with innovative and strong intellectual content that are scalable across international markets. It also manages co-investment funds administered under Startup SG Equity, a scheme which catalyses private-sector investment for start-ups through government equity co-investment. Under Startup SG Equity, SSC supports early-stage start-ups across a wide range of technology and industry domain areas. For more information on the funding programmes, please visit www.spring.gov.sg and www.startupsg.net.

About SPRING Singapore

SPRING Singapore is an agency under the Ministry of Trade and Industry responsible for helping Singapore enterprises grow and building trust in Singapore products and services. As the enterprise development agency, SPRING works with partners to help enterprises in financing, capability and management development, technology and innovation, and access to markets. As the national standards and accreditation body, SPRING develops and promotes an internationally-recognised standards and quality assurance infrastructure. SPRING also oversees the safety of general consumer goods in Singapore.

SPRING will merge with IE Singapore to form Enterprise Singapore in Q2 2018. Enterprise Singapore will enable the growth of Singapore companies through an integrated support network to build business capabilities and access overseas markets.

Please visit <http://www.spring.gov.sg> and <http://www.facebook.com/sgspring> for more information and news about SPRING Singapore.